

1 **Clinical evaluation of the molecular-based BD SARS-CoV-2/Flu for the BD MAX™ System**

2

3 Sonia Paradis, MS,^a Elizabeth Lockamy, PhD,^a Charles K. Cooper, MD,^a Stephen Young, PhD^b

4

5 ^aBecton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, 7

6 Loveton Circle, Sparks, MD, USA

7 ^bTricore Reference Laboratory, 1001 Woodward Place, N.E., Albuquerque, NM, USA

8

9 **#To whom correspondence should be addressed:**

10 Stephen Young, PhD

11 Title: Medical Director of Research and Clinical Trials

12 Address: 1001 Woodward Place, N.E. Albuquerque, NM 87102

13 Telephone: 505-938-8855

14 Email: Steve.Young@Tricore.org

15

16 **##To whom correspondence should be addressed (alternate):**

17 Charles K. Cooper, MD

18 Vice President of Medical Affairs

19 Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions

20 7 Loveton Circle, Sparks MD 21152, USA

21 Phone: 410-316-4984

22 E-mail: Charles_K_Cooper@bd.com

23

24 **WORD COUNT:** 2350

25

26 **RUNNING TITLE:** SARS-CoV-2, Flu multiplex molecular assay

27 **ABSTRACT**

28 *Objectives*

29 Establish the diagnostic performance related to SARS-CoV-2 and Flu A/B detection for the BD
30 SARS-CoV-2/Flu for BD MAX™ System (“MAX SARS-CoV-2/Flu”) multiplex assay.

31

32 *Methods and Materials*

33 Two hundred and thirty-five (235) retrospective nasopharyngeal specimens were obtained from
34 external vendors. The BD BioGx SARS-CoV-2 Reagents for BD MAX™ System (“BioGx
35 SARS-CoV-2”) and the Cepheid Xpert® Xpress Flu/RSV (“Xpert Flu”) were utilized as
36 reference methods.

37

38 *Results*

39 By reference methods, 52 specimens were SARS-CoV-2-positive, 59 were Flu A-positive, and
40 60 were Flu B-positive. MAX SARS-CoV-2/Flu had positive percent agreement (PPA) and
41 negative percent agreement (NPA) values for SARS-CoV-2 detection of 96.2% ([95%CI]:87.0-
42 98.9) and 100% [95%CI:88.7-100], respectively; PPA values for Flu A and Flu B of 100%
43 [95%CI:93.9-100] and 98.3% [95%CI:91.1-99.7], respectively, and NPA values for Flu A and
44 Flu B of 98.9% [95%CI:94.0- 99.8] and 100% [95%CI:95.9-100], respectively.

45

46 *Discussion*

47 The MAX SARS-CoV-2/Flu assays met FDA-EUA performance criteria for SARS-CoV-2
48 ($\geq 95\%$ for PPA and NPA) and FDA clearance criteria for Flu A/B (PPA $\geq 90\%$; lower bound of
49 the 95%CI $\geq 80\%$) and (NPA $\geq 95\%$; lower bound of the 95%CI $\geq 90\%$).

50

51 **KEY WORDS**

52 BD MAX; COVID-19; SARS-CoV-2; Influenza; multiplex RT-PCR assay

53 INTRODUCTION

54 Since the report of the first cluster of COVID-19 cases in December 2019, over 147 million
55 COVID-19 cases and 3 million COVID-19-related deaths worldwide have been reported by the
56 end of April, 2021, and the numbers continue to rise.(1) In the US, more than 32.1 million
57 COVID-19 cases and over 572,000 COVID-19 deaths have been recorded through end of April
58 2021.(2) Although it seems that the 2020-2021 influenza season will not impact the health care
59 systems, the 2019-2020 flu season resulted in over 38 million cases involving symptomatic
60 illness and approximately 22,000 deaths in the US.(3) Each year, there are an estimated 1 billion
61 cases of influenza globally, of which, 3-5 million are severe cases and 29,000-655,000 lead to
62 influenza-related respiratory deaths.(4) Although as of April 2021 influenza activity is low,(5)
63 this virus has the potential of increasing the workload of healthcare workers already
64 overwhelmed by COVID-19.

65
66 While COVID-19 and influenza spread through a similar mechanism of transmission and have
67 overlapping symptoms, including cough and fever, the isolation length and the therapeutic
68 approach for COVID-19 patients and influenza patients are not uniform.(6) The recommended
69 isolation period after symptoms onset is a minimum of 4-5 days for flu,(7) whereas it is a
70 minimum of 10 days for COVID-19,(8) impacting absenteeism and contact tracing. Additionally,
71 the therapeutic interventions vary between these two diseases. The impact of anti-viral drug
72 therapy, such as Tamiflu[®] or Xoflusa, which have been used for influenza patients,(9) are not
73 approved or their efficacy well-understood for patients with COVID-19. Therefore, safety
74 concerns may preclude any potential efficacy. A similar concern exists for drugs such as
75 remdesivir and corticosteroids, which have been used to treat COVID-19 patients, but are not

76 approved for use in influenza patients, and may (for example, in the case of corticosteroids) have
77 negative side effects in influenza patients.(6) As the society gradually reopens the social
78 interactions in many places, the potential coincidence of both COVID-19 and influenza cases in
79 high numbers during respiratory virus seasons is a significant concern. Especially since the
80 respiratory virus activity usually peaks between December and February in the US,(10) and in
81 future respiratory virus seasons could produce a significant strain on the healthcare system.
82 Therefore, differential diagnosis of COVID-19 and influenza, will be an important component
83 for proper patient triage, management, and treatment.

84
85 Molecular diagnostics for the detection of SARS-CoV-2, including real-time polymerase chain
86 reaction (RT-PCR) assays, have played an important role in the detection of SARS-CoV-2 and
87 diagnosis of COVID-19 due to their high sensitivity.(11) Similarly, RT-PCR-based detection of
88 Influenza A/B (“Flu A/B”) virus nucleic acid has been established for a number of years and is
89 commonly employed to establish an influenza diagnosis.(12) Due to the expected co-circulation
90 with the potential co-infection of SARS-CoV-2 and Flu A/B, a multiplex RT-PCR assay, for
91 detection all three targets, could help provide faster results and improve patient management and
92 treatment.(13) This report describes the performance of the new BD SARS-CoV-2/Flu assay
93 reagents for BD MAX™ System multiplex assay for detection of SARS-CoV-2 and Flu A/B.
94 The comparator reference methods were the BD BioGx SARS-CoV-2 Reagents for BD MAX™
95 System and Cepheid Xpert® Xpress Flu/RSV. The objective here was to determine the
96 performance characteristics of the new multiplex BD SARS-CoV-2/Flu assay.

97 **MATERIALS AND METHODS**

98 *Specimens and assays*

99 This study, which was conducted as part of a Food and Drug Administration-Emergency Use
100 Authorization (EUA) submission, included data comparing the BD SARS-CoV-2/Flu for BD
101 MAX™ System (“MAX SARS-CoV-2/Flu;” Becton, Dickinson and Company; BD Life
102 Sciences—Integrated Diagnostics Solutions, Sparks, MD, USA) with reference methods, BD
103 BioGx SARS-CoV-2 Reagents for BD MAX™ System (“BioGx SARS-CoV-2;” Becton,
104 Dickinson and Company; BD Life Sciences – Integrated Diagnostics Solutions, Sparks, MD,
105 USA) and Cepheid Xpert® Xpress Flu/RSV (“Xpert Flu;” Cepheid®, Sunnyvale, CA, USA), for
106 detection of SARS-CoV-2 and Flu A/B, respectively.(14) The BioFire® Respiratory 2.1 Panel
107 (“BioFire SARS-CoV-2;” BioFire Diagnostics, Salt Lake City, UT, USA) was used to test
108 specimens for which MAX SARS-CoV-2/Flu and BioGx SARS-CoV-2 provided discrepant
109 results; the cobas® Influenza A/B & RSV assay for use on the cobas® Liat® System (“Liat Flu;”
110 Roche Diagnostics, Indianapolis, IN, USA) was used to test specimens for which MAX SARS-
111 CoV-2/Flu and Xpert Flu provided discrepant results. All assays were performed according to
112 each manufacturer’s instructions for use. MAX SARS-CoV-2/Flu, BioGx SARS-CoV-2, and
113 BioFire SARS-CoV-2 assays were performed at BD Integrated Diagnostics Solutions; Xpert Flu
114 and Liat Flu assays were performed at TriCore Reference Laboratories (Table S1).
115
116 Nasopharyngeal specimens for SARS-CoV-2 testing were obtained from New York Biologics,
117 Inc. (Southampton, NY, USA) and Trans-Hit Bio (Laval, QC, Canada), and nasopharyngeal
118 specimens for Flu A/B testing were obtained from New York Biologics, Inc. Specimens
119 provided by New York Biologics were collected under protocols approved by Western

120 Institutional Review Board (WIRB) and from Ethical & Independent Review Services (EIRS).
121 These institutional review board approvals provide a waiver of informed consent on collection
122 protocols for de-linked and de-identified specimen collections. Samples obtained from Trans-Hit
123 Bio were collected under their biobank umbrella protocol (approved by the Valleywise Health
124 Institutional Review Board) that allows for the collection of various bio-specimens. Two hundred
125 and thirty-five (235) nasopharyngeal specimens either in Copan Universal Transport Medium
126 (UTM[®]) or in BD Universal Viral Transport (UVT) system were collected between November
127 30, 2019 to September 3, 2020. The samples were obtained from individuals with ages ranging
128 from ≤ 5 years of age to ≥ 60 years of age and the residual transport media was stored at $-65^{\circ}\text{C} \sim$
129 -80°C (Table 1).

130
131 The specimens were collected as part of standard of care (SOC) and residual de-identified
132 samples were frozen and used for this research. This article was prepared according to STARD
133 guidelines for diagnostic accuracy studies reporting.(15)

134
135 *Data analysis*

136 The primary outcome measures for this study were positive and negative percent agreement
137 (PPA and NPA, respectively) point estimates (with 95% confidence interval [95% CI] calculated
138 using the Wilson score method) for the MAX SARS-CoV-2/Flu assay, compared to each
139 respective reference assay. The McNemar test was used for 2x2 classification to test the
140 difference between paired proportions. The calculated difference is that of marginal proportions
141 ([total proportion of SARS-CoV-2, Flu A, or Flu B positives] – [total proportion of positives (for
142 each of the three causes) by clinical diagnosis]). A p-value < 0.05 was utilized to distinguish

143 significant differences (note here that a p-value >0.05 indicates only that disagreement between
144 the two diagnostics methods is random). The Cohen's kappa coefficient was utilized to gauge the
145 agreement between two raters (reference and test) to classify results into mutually exclusive
146 categories. $K=(P_o - P_e)/1 - P_e$ (<0, 0, and >0 indicating agreements worse than, no better or worse
147 than, and better than that expected by chance). Acceptance criteria for the MAX SARS-CoV-
148 2/Flu assay for US FDA-EUA authorization for SARS-CoV-2 was $\geq 95\%$ for both PPA and
149 NPA.(16) The PPA criteria for Flu A/B was $\geq 90\%$ (lower bound of the 95%CI $\geq 80\%$) and the
150 NPA criteria for Flu A/B was $\geq 95\%$ (lower bound of the 95%CI $\geq 90\%$). Only compliant and
151 reportable results for both MAX SARS-CoV-2/Flu and comparator assays were included in this
152 analysis.

153

154 *Data Availability*

155 Data will be made publicly available upon publication and upon request for peer review.

156 **RESULTS**

157 235 specimens were included in this study, from which, three were excluded due to unreportable
158 results from an instrumental failure. From the remaining 232 specimens, reference method
159 testing for SARS-CoV-2 (BioGx SARS-CoV-2) and Flu A/B (Xpert Flu), resulted in 52 positive
160 SARS-CoV-2 specimens, 59 positive Flu A specimens, and 60 positive Flu B specimens (Table
161 1). By reference methods, 30, 91, and 90 specimens were negative, respectively, for SARS-CoV-
162 2, Flu A, and Flu B. Among all positive cases, the 22-59 years age group had the highest SARS-
163 CoV-2 positivity, the ≤ 5 age group had the highest Flu A positivity, and the 6-21 years age group
164 had the highest Flu B positivity.

165
166 MAX SARS-CoV-2/Flu results were compared to results from each respective reference method
167 to determine PPA and NPA values. MAX SARS-CoV-2/Flu had PPA and NPA values of 96.2%
168 [95%CI: 87.0, 98.9] and 100% [95%CI: 88.7, 100], respectively, for detection of SARS-CoV-2.
169 For Flu A, MAX SARS-CoV-2/Flu had PPA and NPA values of 100% [95%CI: 93.9, 100] and
170 98.9% [95%CI: 94.0, 99.8], respectively. For Flu B, MAX SARS-CoV-2/Flu had PPA and NPA
171 values of 98.3% [95%CI:91.1, 99.7] and 100% [95%CI: 95.9, 100], respectively (Table 2).

172
173 During discordant testing, the MAX SARS-CoV2/Flu assay was in agreement with the third
174 assays (i.e. BioFire SARS-Cov-2 assay and Liat Flu assay) for both SARS-CoV-2 negative
175 results and for the Flu A positive result by the MAX SARS-CoV-2/Flu assay. For Flu B, the Liat
176 Flu assay agreed with the Xpert Flu assay negative result. However, all discrepant results were
177 associated with high cycle threshold (Ct) values (ranging from 37.8 to 39.5). The MAX SARS-

178 CoV-2 showed 100% PPA in specimens with reference method results associated with Ct values
179 ≤ 30 (Table 3).

180 **DISCUSSION**

181 The results here show PPA for the MAX SARS-CoV-2/Flu assay with reference assays meet
182 FDA-EUA acceptance criteria for detection of SARS-CoV-2 (96.2%), Flu A (100%; with a
183 lower bound 95%CI of 93.9%), and Flu B (98.3%; with a lower bound 95%CI of 91.1%).
184 Similarly, compared to reference methods, the MAX SARS-CoV-2/Flu assay was associated
185 with NPA values for detection of SARS-CoV-2 (100%), Flu A (98.9%; with a lower bound
186 95%CI of 94.0%), and Flu B (100%; with a lower bound 95%CI of 95.9%) that all met FDA
187 acceptance criteria. Discordant results were further tested with the third assays, BioFire SARS-
188 CoV-2 assay SARS-CoV-2 and Liat Flu assay for Flu A/B. All discrepant results were associated
189 with high Ct values. Thus, with its high PPA and NPA for SARS-CoV-2, Flu A, and Flu B, this
190 multiplex assay should reduce specimen collection time and the amount of supplies and reagents
191 necessary to test for both COVID-19 and Flu.

192
193 Different approaches are currently available for the detection of SARS-CoV-2 and Flu A/B for
194 the diagnosis of both COVID-19 and influenza, respectively.(12, 17) Although culture-based
195 assays were originally utilized to establish an influenza diagnosis, RT-PCR-based technology for
196 diagnosis of influenza currently represents the laboratory method of choice due to its relatively
197 high analytic and clinical sensitivity, as well as short turn-around time.(18) Likewise, RT-PCR-
198 based assays appear to have higher sensitivity for detection for SARS-CoV-2 compared to
199 culture-based assays.(19) Rapid testing, such as immunochromatic techniques are used to detect
200 viral antigen, have been developed for detection of both SARS-CoV-2 and Flu A/B.(11, 12)
201 Although rapid tests carry advantages, such as decreased time-to-result and ease of
202 implementation in decentralized health care settings, RT-PCR-based assays have increased

203 analytical sensitivity compared to rapid tests.(12) Ultimately, multiple factors should be
204 considered before determining which strategy should be employed. For example, hospitals and
205 their associated laboratory partners, which have established a streamlined workflow and a
206 relatively fast turn-around-time, can effectively employ RT-PCR-based assays—especially for
207 patients admitted and managed according to their symptoms. This strategy carries the benefit of
208 high sensitivity and the ability to rule out etiologic agents with a high degree of assurance.

209
210 The MAX SARS-CoV-2/Flu assay utilizes the same multiplexed primers and probes targeting
211 RNA from the nucleocapsid phosphoprotein gene (N1 and N2 regions) of the SARS-CoV-2 virus
212 as shown in the previous FDA-EUA approved MAX SARS-CoV-2 assay.(20) The MAX SARS-
213 CoV-2/Flu assay also includes additional primers and probes recognizing a conserved region of
214 the matrix protein M1 gene for influenza A and conserved regions of the matrix protein M1 gene
215 and hemagglutinin (HA) gene for influenza B.(21) A positive result for SARS-CoV-2 with a low
216 Ct value may be indicative of active infection, however, this result does not rule out bacterial
217 infection or co-infection with other viruses.(20) This is important in the case of SARS-CoV-2, as
218 asymptomatic infections are possible and the positive results require clinical judgement. While
219 the MAX SARS-CoV-2/Flu assay can detect SARS-CoV-2 and influenza A and B virus, it is not
220 intended to detect influenza C virus.(21) The clinical presentation and contact history of an
221 individual along with other diagnostic information is necessary to determine the actual infection
222 status.

223
224 If the coincidence of high rates of both COVID-19 and influenza cases occurs during a
225 respiratory virus season, differential diagnosis for the appropriate therapeutic approach could be

226 challenging. Although COVID-19 and influenza spread through a similar transmission
227 mechanism and have overlapping symptomology, specific differences between the diseases do
228 exist. For example, COVID-19 seems to involve a longer time to symptom onset than influenza,
229 and may cause more severe illness in vulnerable populations once symptoms develop.(22) Also,
230 the therapeutic approach for COVID-19 patients and influenza patients is not similar. While the
231 impact of anti-viral drug for influenza patients is standardized, this is not the case for the
232 treatment SARS-CoV-2-positive individuals. Medications such as remdesivir and/or
233 corticosteroids have been used to treat COVID-19 patients, however, these two approaches are
234 not approved for use in influenza patients.(6) Distinguishing the diagnosis of COVID-19 and
235 influenza, therefore, will be an important component for proper patient triage, management, and
236 treatment.

237

238 *Limitations*

239 This research was conducted by using materials obtained from pre-selected frozen remnants,
240 received after routine care. A study involving prospective collection would better inform on the
241 positive and negative predictive values of the assay.

242

243 *Conclusions*

244 The MAX SARS-CoV-2/Flu assays met US FDA-EUA acceptance criteria for SARS-CoV-2 and
245 Flu A/B detection. Dual detection of the etiologic agents causing COVID-19 and influenza will
246 allow differentiation for those exhibiting common symptoms between the two diseases. This
247 assay should help optimize patient management by decreasing the time and resources required
248 for dual testing. Ultimately, the dual detection method should facilitate an informed decision by

249 physicians on the appropriate treatment for patients exhibiting similar symptoms between the
250 two diseases.

251 **ACKNOWLEDGEMENTS**

252 We thank Karen Eckert and Karen Yanson (Becton, Dickinson and Company, BD Life Sciences
253 – Integrated Diagnostic Solutions) for their input on the study logistics and content of this
254 manuscript and editorial assistance. We also thank Yu-Chih Lin and Devin Gary for the editorial
255 assistance. We thank Stanley Chao, Aojun Li, and Yongqiang Zhang (Becton, Dickinson and
256 Company, BD Life Sciences – Integrated Diagnostic Solutions) for statistical support. The
257 individuals acknowledged here have no additional funding or additional compensation to
258 disclose. We are grateful to the study participants who allowed this work to be performed.

259

260 **AUTHOR CONTRIBUTIONS**

261 **Sonia Paradis:** Conceptualization, Resources, Writing – Original Draft, Writing – Review &
262 Editing, Visualization, Project administration. **Elizabeth Lockamy:** Methodology, Formal
263 analysis, Investigation, Resources, Data curation, Writing – Review & Editing. **Charles K.**
264 **Cooper:** Conceptualization, Supervision, Writing – Review & Editing. **Stephen**
265 **Young:** Conceptualization, Methodology, Formal analysis, Investigation, Resources, Data
266 Curation, Writing – Review & Editing, Supervision, Project administration, Funding acquisition.

267

268 **FUNDING**

269 This study was funded by Becton, Dickinson and Company; BD Life Sciences—Integrated
270 Diagnostics Solutions. Non-BD employee authors received research funds to support their work
271 for this study.

272

273 **POTENTIAL CONFLICTS OF INTEREST**

274 The authors disclose the following conflicts of interest: SP, EL, and CKC are employees of

275 Becton, Dickinson and Company; SY, None.

276

277 **REFERENCES**

- 278 1. Wu Z, McGoogan JM. 2020. Characteristics of and Important Lessons From the
279 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of
280 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA
281 323:1239-1242.
- 282 2. Johns Hopkins University and Medicine, Coronavirus Resource Center. 2020. Mortality
283 Analyses. <https://coronavirus.jhu.edu/data/mortality>.
- 284 3. Centers for Disease Control and Prevention. Estimated Influenza Illness, Medical Visits,
285 Hospitalizations, and Deaths in the United States-2019-2020 Influenza Season. 2020.
286 <https://www.cdc.gov/flu/about/burden/2019-2020.html>.
- 287 4. Global influenza strategy 2019-2030. Geneva: World Health Organization; 2019.
288 Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are
289 available at <http://apps.who.int/iris>.
- 290 5. World Helath Organization. Influenza Update - 383. Accessed December 28, 2020.
291 [https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surve](https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/)
292 [illance/en/](https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/).
- 293 6. Kaur SP, Gupta V. 2020. COVID-19 Vaccine: A comprehensive status report. Virus
294 research 288:198114-198114.
- 295 7. Centers for Disease Control and Prevention. Stay at home when you are sick. Accessed
296 December 28, 2020. [https://www.cdc.gov/flu/business/stay-home-when-](https://www.cdc.gov/flu/business/stay-home-when-sick.htm#:~:text=Individuals%20with%20suspected%20or%20confirmed,3%20days%20of%20their%20illness)
297 [sick.htm#:~:text=Individuals%20with%20suspected%20or%20confirmed,3%20days%20](https://www.cdc.gov/flu/business/stay-home-when-sick.htm#:~:text=Individuals%20with%20suspected%20or%20confirmed,3%20days%20of%20their%20illness)
298 [of%20their%20illness](https://www.cdc.gov/flu/business/stay-home-when-sick.htm#:~:text=Individuals%20with%20suspected%20or%20confirmed,3%20days%20of%20their%20illness).

- 299 8. Centers for Disease Control and Prevention. Options to reduce quarantine for contacts of
300 persons with SARS-CoV-2 infection using symptom monitoring and diagnostic testing.
301 Accessed December 28, 2020. [https://www.cdc.gov/coronavirus/2019-
302 \[ncov/more/scientific-brief-options-to-reduce-quarantine.html\]\(https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-quarantine.html\).](https://www.cdc.gov/coronavirus/2019-ncov/more/scientific-brief-options-to-reduce-quarantine.html)
- 303 9. U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) Information. 2018.
304 [https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-
305 providers/tamiflu-oseltamivir-phosphate-information](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/tamiflu-oseltamivir-phosphate-information).
- 306 10. Centers for Disease Control and Prevention. The Flu Season. Accessed March 22, 2021.
307 <https://www.cdc.gov/flu/about/season/flu-season.htm>.
- 308 11. Cheng MP, Papenburg J, Desjardins M, Kanjilal S, Quach C, Libman M, Dittrich S,
309 Yansouni CP. 2020. Diagnostic Testing for Severe Acute Respiratory Syndrome–Related
310 Coronavirus 2. *Annals of Internal Medicine* 172:726-734.
- 311 12. Vemula SV, Zhao J, Liu J, Wang X, Biswas S, Hewlett I. 2016. Current Approaches for
312 Diagnosis of Influenza Virus Infections in Humans. *Viruses* 8:96-96.
- 313 13. Rubin R. 2020. What Happens When COVID-19 Collides With Flu Season? *JAMA*
314 324:923-925.
- 315 14. U.S. Food and Drug Administration. 2021. BD SARS-CoV-2/Flu for BD MAX System -
316 Letter of Authorization.
- 317 15. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG,
318 Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L,
319 Korevaar DA, Cohen JF. 2015. STARD 2015: An Updated List of Essential Items for
320 Reporting Diagnostic Accuracy Studies. *Radiology* 277:826-32.

- 321 16. U.S. Food and Drug Administration. Coronavirus Disease 2019 (COVID-19) Emergency
322 Use Authorization for Medical Devices--In Vitro Diagnostics EUAs.
323 [https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular)
324 [use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#individual-molecular).
- 325 17. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. 2020. Testing for
326 SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and
327 serological in-vitro diagnostic assays. *Reprod Biomed Online* 41:483-499.
- 328 18. Centers for Disease Control and Prevention. Influenza (Flu). Accessed December 16,
329 2020. <https://www.cdc.gov/flu/professionals/diagnosis/overview-testing-methods.htm>.
- 330 19. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodsi S, Gary DS, Roger-Dalbert
331 C, Leitch J, Cooper CK. 2021. Antigen-Based Testing but Not Real-Time Polymerase
332 Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral
333 Culture. *Clin Infect Dis* doi:10.1093/cid/ciaa1706.
- 334 20. BD SARS-CoV-2 Reagents for BD MAX™ System [package insert]. Becton, Dickinson
335 and Company, Sparks-Glencoe, MD; 2020.
- 336 21. BD SARS-CoV-2/Flu for BD MAX™ System [package insert]. Becton, Dickinson and
337 Company, Sparks-Glencoe, MD; 2020.
- 338 22. Centers for Disease Control and Prevention. Similarities and differences between Flu and
339 COVID-19. Accessed December 28, 2020. [https://www.cdc.gov/flu/symptoms/flu-vs-](https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20symptoms%20listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20taste%20or%20smell)
340 [covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20sympto](https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20symptoms%20listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20taste%20or%20smell)
341 [ms%20listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20](https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20symptoms%20listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20taste%20or%20smell)
342 [taste%20or%20smell](https://www.cdc.gov/flu/symptoms/flu-vs-covid19.htm#:~:text=Flu%20viruses%20can%20cause%20mild,signs%20and%20symptoms%20listed%20above.&text=COVID%2D19%20seems%20to%20cause,loss%20of%20taste%20or%20smell).
- 343

Table 1. SARS-CoV-2 and influenza positivity by reference method or MAX SARS-CoV-2/Flu across age groups.

Age group	Reference			BD MAX SARS-CoV-2/Flu		
	SARS-CoV-2 n (%)	Influenza A n (%)	Influenza B n (%)	SARS-CoV-2 n (%)	Influenza A n (%)	Influenza B n (%)
≤5 years 21.6% (n=50)	0 (0.0)	19 (32.2)	13 (21.7)	0 (0.0)	19 (31.7)	13 (22.0)
6-21 years 19.8% (n=46)	0 (0.0)	12 (20.3)	26 (43.3)	0 (0.0)	12 (20.0)	26 (44.1)
22-59 years 41.8% (n=97)	39 (75.0)	16 (27.1)	16 (26.7)	37 (74.0)	17 (28.3)	15 (25.4)
≥60 years 16.8% (39)	13 (25.0)	12 (20.3)	5 (8.3)	13 (26.0)	12 (20.0)	5 (8.5)
Overall (N=232)^a	52	59	60	50	60	59

^aCompliant and reportable for MAX and comparator assays.

Table 2. Performance of the MAX SARS-CoV-2/Flu assay for detection of SARS-CoV-2, Flu A and Flu B compared to reference.

	SARS-CoV2 ^{a,c}	Flu A ^{b,c}	Flu B ^{b,c}
PPA	96.2% [87.0%, 98.9%]	100% [93.9%, 100%]	98.3% [91.1%, 99.7%]
NPA	100% [88.7%, 100%]	98.9% [94.0%, 99.8%]	100% [95.9%, 100%]
MAX (+) / Ref (+)	50	59	59
MAX (+) / Ref (-)	0	1	0
MAX (-) / Ref (+)	2	0	1
MAX (-) / Ref (-)	30	90	90
kappa	0.948	0.986	0.986

Abbreviations: PPA, positive percent agreement; NPA, negative percent agreement

^aReference method was the BioGx SARS-CoV-2 RT-PCR assay.

^bReference method was the Xpert Flu RT-PCR assay.

^cA statistically significant difference (via McNemar's test on paired proportions) was not observed for MAX SARS-CoV-2/Flu for detection of SARS-CoV-2 (-2.4 [95% CI: -5.8, 0.0]; p=0.500), Flu A (0.67 [95% CI: -0.64, 1.97]; p=1.000), or Flu B (-0.67 [95% CI: -1.97, 0.64]; p=1.000).

Table 3. Comparison of MAX SARS-CoV-2/Flu assay results with those from the BioGx SARS-CoV-2 and Xpert Flu assays, stratified by cycle threshold category.

BioGx SARS-CoV-2		
MAX SARS-CoV-2	Positive (Ct ≤ 30)	Positive (Ct > 30)
Positive	41	9
Negative	0	2 ^a
Total	41	11
PPA (95% CI)	100% (91.4% - 100%)	81.8% (52.3% - 94.9%)

MAX Flu A	Xpert Flu A^b	
MAX	Positive (Ct ≤ 30)	Positive (Ct > 30)
Positive	48	11
Negative	0	0
Total	48	11
PPA (95% CI)	100% (92.6% - 100%)	100% (74.1% - 100%)

MAX Flu B	Xpert Flu B	
MAX	Positive (Ct ≤ 30)	Positive (Ct > 30)
Positive	48	11
Negative	0	1 ^c
Total	48	12
PPA (95% CI)	100% (92.6% - 100%)	91.7% (64.6% - 98.5%)

Abbreviations: Ct, PCR cycle threshold; PPA, positive percent agreement

^aOne specimen corresponded to a Ct value for the N1 result = 39.5 and an N2 result = negative. One specimen corresponded to a N1 result = negative and a Ct value for the N2 result = 38.8. Discrepancy testing with the BioFire SARS-CoV-2 assay was positive (agreement with MAX) for both specimens.

^bOne specimen (not shown here) was positive by MAX (Ct value = 38.8) and negative by Xpert Flu. Discrepancy testing with the Liat Flu assay was positive (agreement with MAX SARS-CoV-2/Flu).

^cCt value for the Xpert Flu result = 37.8. Discrepancy testing with the Liat Flu assay was positive (agreement with Xpert Flu).

Table S1. Study assays and locations for assay performance.

Assay	BD (Sparks, MD)	TriCore (Albuquerque, NM)
BD MAX SARS-CoV-2/Flu ^{a,b}	√	
BioGx SARS-CoV-2 ^{a, c}	√	
Xpert Flu ^{b, d}		√
BioFire SARS-CoV-2 ^{a, e}	√	
Liat Flu ^{b, f}		√

^aSpecimens for SARS-CoV-2 testing were obtained from New York Biologics (Southampton, NY) and Trans-Hit Bio (Laval, QC, Canada).

^bSpecimens for Flu A/B testing were obtained from New York Biologics.

^cUtilized for reference test during detection of SARS-CoV-2.

^dUtilized for reference test during detection of Flu A/B.

^eUtilized for discordant test involving detection of SARS-CoV-2.

^fUtilized for discordant test involving detection of Flu A/B.